aibio
Debt Financing ·
Elicio Therapeutics takes $10 million secured loan from investor GKCC
The note carries interest of up to 12.5% and matures on June 3, 2028. Elicio expects the cash to fund operations into the first quarter of 2026.
ELTX Elicio Therapeutics, Inc.
Elicio Therapeutics (ELTX) news
Latest Elicio Therapeutics news
We have not published a story on Elicio Therapeutics yet. When there is news, it will appear here.
Elicio Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $24.9 million | $33.7 million |
| Net income (loss) | -$39.6 million | -$51.9 million |
| Cash from operations | -$37.0 million | -$37.1 million |
| Cash and equivalents | $18.6 million | $17.6 million |
Questions about Elicio Therapeutics
What is the ticker symbol of Elicio Therapeutics?
Elicio Therapeutics, Inc. trades under the ticker ELTX on NASDAQ.
Where is Elicio Therapeutics listed?
Elicio Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9HA.
What is the SEC CIK of Elicio Therapeutics?
The SEC Central Index Key (CIK) for Elicio Therapeutics, Inc. is 1601485. Its filings are on SEC EDGAR.
How many shares does Elicio Therapeutics have outstanding?
26,281,882 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Elicio Therapeutics listed under?
Our directory records Elicio Therapeutics, Inc. under United States.
What does Elicio Therapeutics do?
Our directory classifies Elicio Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Elicio Therapeutics?
The ISIN recorded for Elicio Therapeutics, Inc. is US28657F1030.
Does aibio.space cover Elicio Therapeutics?
aibio.space lists Elicio Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Elicio Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Elicio Therapeutics profitable?
Elicio Therapeutics, Inc. reported a net loss of $39.6 million for the fiscal year ended Dec 31, 2025, and used $37.0 million of cash in operations, per its annual report to the SEC.
How much does Elicio Therapeutics spend on research and development?
$24.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Elicio Therapeutics have?
$23.5 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Elicio Therapeutics (ELTX) stock news?
Our latest story on Elicio Therapeutics, dated Jun 4, 2025: "Elicio Therapeutics takes $10 million secured loan from investor GKCC". The note carries interest of up to 12.5% and matures on June 3, 2028. Elicio expects the cash to fund operations into the first quarter of 2026. Source.
Does Elicio Therapeutics have debt, a term loan or convertible notes?
Our latest debt story, dated Jun 4, 2025: "Elicio Therapeutics takes $10 million secured loan from investor GKCC". The note carries interest of up to 12.5% and matures on June 3, 2028. Elicio expects the cash to fund operations into the first quarter of 2026. Source.
How long will Elicio Therapeutics's cash last?
From our story of Jun 4, 2025: Elicio expects the cash to fund operations into the first quarter of 2026. Source.
Investor discussion: Elicio Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,1.02). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
- Financings
Reported a financing. SEC Form 424B5. Source
Stock chart
SEC filings and registration
- SEC name
- Elicio Therapeutics, Inc.
- CIK
- 1601485
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ELTX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 451 D STREET, 5TH FLOOR, BOSTON, MA, 02210
- Phone
- (857) 209-0050
- Shares outstanding
- 26,281,882 as of 2026-08-11 (10-Q filed 2026-08-13)
- Former names
- Angion Biomedica Corp.
Recent filings
Listing details
- Company
- Elicio Therapeutics, Inc.
- Ticker
- ELTX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US28657F1030
- Other listed symbols
- GETTEX:9HA
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction